Modulation of CCL5 and CXCR4 as EMT signaling biomarkers by cold atmospheric plasma and Anti-PD-1 combination therapy in melanoma: Insights from integrated bioinformatics and in vitro and in vivo validation

Articles in Press

Document Type : Original Article

Authors

1 Department of Immunology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

2 Student Research Committee, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

3 Department of Genetics, Faculty of Basic Sciences, Shahrekord University, Shahrekord, Iran

4 Gastrointestinal Cancer Research Center, Non-Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran

5 Department of Anatomy, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

10.22038/ijbms.2026.91340.19707

Abstract

Objective(s): Cold atmospheric plasma (CAP) has emerged as a promising non-thermal modality with anticancer effects. Combining CAP with immune checkpoint blockade (ICB) may enhance therapeutic efficacy, yet the molecular targets underlying this synergy remain incompletely understood.
Materials and Methods: Epithelial–mesenchymal transition (EMT)–associated genes responsive to CAP and Anti-PD-1 therapy were identified by integrating bioinformatics analyses of melanoma transcriptomic data with in vitro and in vivo experiments. Weighted gene co-expression network analysis (WGCNA), GO, and KEGG enrichment identified key modules and candidate genes. The effects of CAP, Anti-PD-1, and their combination on cell viability and gene expression were evaluated in B16F10 melanoma cells, L929 fibroblasts, and a syngeneic mouse melanoma model.
Results: WGCNA highlighted CCL5 and CXCR4 as hub genes enriched in EMT-related pathways. MTT assays showed that CAP reduced B16F10 cell viability, an effect further enhanced by Anti-PD-1, while sparing L929 fibroblasts. In tumor-bearing mice, combination therapy produced the most pronounced tumor regression and down-regulation of CCL5 and CXCR4 compared with single treatments. Minimal viability or expression changes were observed in normal fibroblasts or untreated controls.
Conclusion: CAP and Anti-PD-1 combination therapy effectively suppressed melanoma cell viability and modulated EMT-associated gene expression both in vitro and in vivo. We further explored a potential molecular mechanism underlying this therapeutic effect, revealing that the EMT-related genes CCL5 and CXCR4 play a vital role in this response. These findings highlight the relevance of these pathways and support the potential of combining CAP with ICB as a promising approach for melanoma treatment.

Keywords

Main Subjects

References

1. Sánchez-Sancho P, Alonso-Martínez C, Renedo-Miró B. Tratamiento con nivolumab en una paciente oncológica trasplantada. El Farmacéutico Hospitales 2022.
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71:209-249.
3. Eddy K, Shah R, Chen S. Decoding melanoma development and progression: Identification of therapeutic vulnerabilities. Front Oncol  2021; 10:626129.
4. Lee L, Ramos-Alvarez I, Jensen RT. Predictive factors for resistant disease with Medical/Radiologic/Liver-directed anti-tumor treatments in patients with advanced pancreatic neuroendocrine neoplasms: Recent advances and controversies. Cancers 2022; 14:1250.
5. Sone K, Kukita A, Masui Y, Yamada D, Shinozaki-Ushiku A, Kawata A, et al. Recurrent malignant melanoma of the uterine cervix treated with anti-PD-1 antibodies and anti-CTLA-4 antibodies: a case report. Mol Clin Oncol 2022; 16:63.
6. McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol  2014; 15:323-332.
7. Sagwal SK, Pasqual-Melo G, Bodnar Y, Gandhirajan RK, Bekeschus S. Combination of chemotherapy and physical plasma elicits melanoma cell death via upregulation of SLC22A16. Cell Death Dis 2018; 9:1179.
8. Hachey SJ, Boiko AD. Therapeutic implications of melanoma heterogeneity. Exp Dermatol 2016; 25:497-500.
9. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science 2018; 359:1350-1355.
10. Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med 2016; 8:328rv4
11. Kleffel S, Posch C, Barthel SR, Mueller H, Schlapbach C, Guenova E, et al. Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth. Cell 2015; 162:1242-1256.
12. Tone M, Iwahori K. PD-1 expression on tumor cells: A new target for cancer therapy. Transl Lung Cancer Res 2024; 13:186-189.
13. Mateu-Sanz M, Ginebra M-P, Tornín J, Canal C. Cold atmospheric plasma enhances doxorubicin selectivity in metastasic bone cancer. Free Radic Biol Med 2022; 189:32-41.
14. Mali SB. Role of Cold atmospheric plasma in cancer management. Oral Oncology Reports 2024; 9:100133.
15. Khalaf AT, Abdalla AN, Ren K, Liu X. Cold atmospheric plasma (CAP): A revolutionary approach in dermatology and skincare. Eur J Med Res 2024; 29:487.
16. Babajani A, Eftekharinasab A, Bekeschus S, Mehdian H, Vakhshiteh F, Madjd Z. Reactive oxygen species from non-thermal gas plasma (CAP): implication for targeting cancer stem cells. Cancer Cell International 2024; 24:344.
17. Khalaf AT, Abdalla AN, Ren K, Liu X. Cold atmospheric plasma (CAP): A revolutionary approach in dermatology and skincare. Eur J Med Res 2024; 29:487.
18. Philippou Y, Sjoberg HT, Murphy E, Alyacoubi S, Jones KI, Gordon-Weeks AN, et al. Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model. Br J Cancer 2020; 123:1089-1100.
19. Cao Y, Ye Q, Ma M, She QB. Enhanced bypass of PD-L1 translation reduces the therapeutic response to mTOR kinase inhibitors. Cell Rep 2023; 42:112764.
20. Chen G, Chen Z, Wen D, Wang Z, Li H, Zeng Y, et al. Transdermal cold atmospheric plasma-mediated immune checkpoint blockade therapy. Proceedings of the National Academy of Sciences 2020; 117:3687-3692.
21. Zhuang J, Yuan Q, Chen C, Liu G, Zhong Z, Zhu K, et al. Nanosecond pulsed cold atmospheric plasma jet suppresses proliferation and migration of human glioblastoma cells via apoptosis promotion and EMT inhibition. Arch Biochem Biophys
2023; 747:109757.
22. Messeha SS, Zarmouh NO, Soliman KF. Polyphenols modulating effects of PD-L1/PD-1 checkpoint and EMT-mediated PD-L1 overexpression in breast cancer. Nutrients 2021; 13:1718.
23. Wang L, Saci A, Szabo PM, Chasalow SD, Castillo-Martin M, Domingo-Domenech J, et al. EMT-and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. Nat Commun 2018; 9:3503.
24. Nieto MA. The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu Rev Cell Dev Biol 2011; 27:347-376.
25. Ye X, Weinberg RA. Epithelial–mesenchymal plasticity: A central regulator of cancer progression. Trends Cell Biol 2015; 25:675-686.
26. Coricovac D, Dehelean C, Moaca E-A, Pinzaru I, Bratu T, Navolan D, et al. Cutaneous melanoma—a long road from experimental models to clinical outcome: A review. Int J Mol Sci 2018; 19:1566.
27. Chen X, Guo W, Xu X-j, Su F, Wang Y, Zhang Y, et al. Melanoma long non-coding RNA signature predicts prognostic survival and directs clinical risk-specific treatments. J Dermatol Sci 2017; 85:226-234.
28. Liu Y, Chen Y, Hu X, Meng J, Li X. Development and validation of the B cell‐associated fc receptor‐like molecule‐based prognostic signature in skin cutaneous melanoma. Biomed Res Int 2020; 2020:8509805.
29. Consortium G, Ardlie KG, Deluca DS, Segrè AV, Sullivan TJ, Young TR, et al. The genotype-tissue expression (GTEx) pilot analysis: Multitissue gene regulation in humans. Science 2015; 348:648-660.
30. Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 2015; 21:938-945.
31. Collado-Torres L, Nellore A, Kammers K, Ellis SE, Taub MA, Hansen KD, et al. Reproducible RNA-seq analysis using recount2. Nat Biotechnol 2017; 35:319-321.
32. Liu J, Li R, Liao X, Hu B, Yu J. Comprehensive investigation of the clinical significance and molecular mechanisms of plasmacytoma variant translocation 1 in sarcoma using genome-wide RNA sequencing data. J Cancer 2019; 10:4961-4977.
33. Huang R, Mao M, Lu Y, Yu Q, Liao L. A novel immune-related genes prognosis biomarker for melanoma: Associated with tumor microenvironment. Aging (Albany NY) 2020; 12:6966-6980.
34. Zhang X, Ping S, Zhang R, Li C, Gao C, Ma H, et al. Development and validation of an immune-related gene pairs signature in lower-grade  II/III glioma. Int J Gen Med. 2021 Nov 23;14:8611–8620
35. Xiao Y, Zhu Z, Li J, Yao J, Jiang H, Ran R, et al. Expression and prognostic value of long non-coding RNA H19 in glioma via integrated bioinformatics analyses. Aging (Albany NY) 2020; 12:3407.
36. Ho DW-H, Kai AK-L, Ng IO-L. TCGA whole-transcriptome sequencing data reveals significantly dysregulated genes and signaling pathways in hepatocellular carcinoma. Front Med 2015; 9:322-330.
37. Robinson MD, McCarthy DJ, Smyth GK. edgeR: A bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010; 26:139-140.
38. Langfelder P, Horvath S. WGCNA: An R package for weighted correlation network analysis. BMC bioinformatics 2008; 9:1-13.
39. Consortium GO. The gene ontology (GO) project in 2006. Nucleic Acids Res  2006; 34:D322-D326.
40. Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res 2000; 28:27-30.
41. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, et al. STRING v10: protein–protein interaction networks, integrated over the tree of life. Nucleic Acids Res 2015; 43:D447-D452.
42. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 2017; 45:W98-W102.
43. Mondal P, Singh P, Mahanti K, Bhattacharyya S. Identification of cancer stem cell (CSC) associated genes, prognostic value and candidate drugs as modulator of CSC associated signaling in carcinomas through a multiomics data analysis approach.  Informatics 2024; 11:95.
44. Appay V, Rowland-Jones SL. RANTES: A versatile and controversial chemokine. Trends Immunol 2001; 22:83-87.
45. Rafiei A, Sohbatzadeh F, Hadavi S, Bekeschus S, Alimohammadi M, Valadan R. Inhibition of murine melanoma tumor growth in vitro and in vivo using an argon-based plasma jet. Clin Plasma Med 2020; 19:100102.
46. Alimohammadi M, Golpour M, Sohbatzadeh F, Hadavi S, Bekeschus S, Niaki HA, et al. Cold atmospheric plasma is a potent tool to improve chemotherapy in melanoma in vitro and in vivo. Biomolecules 2020; 10:1011.
47. Yazdani Z, Mehrabanjoubani P, Rafiei A, Biparva P, Kardan M. Combined effect of cold atmospheric plasma and curcumin in melanoma cancer. Biomed Res Int 2021; 2021:1969863.
48. Capasso A, Lang J, Pitts TM, Jordan KR, Lieu CH, Davis SL, et al. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. J Immunother Cancer 2019; 7:37.
49. Stuckey JE, Makhija SD, Reimer DC, Eswaraka JR. Effects of different grades of carbon dioxide on euthanasia of mice (Mus musculus). J Am Assoc Lab Anim Sci 2023; 62:430-437.
50. Festing MF, Altman DG. Guidelines for the design and statistical analysis of experiments using laboratory animals. ILAR J
2002; 43:244-258.
51. Dakup PP, Porter KI, Little AA, Zhang H, Gaddameedhi S. Sex differences in the association between tumor growth and T cell response in a melanoma mouse model. Cancer Immunol Immunother 2020; 69:2157-2162.
52. Song X, Zhou X, Qin Y, Yang J, Wang Y, Sun Z, et al. Emodin inhibits epithelial‑mesenchymal transition and metastasis of triple negative breast cancer via antagonism of CC‑chemokine ligand 5 secreted from adipocytes. Int J Mol Med 2018; 42:579-588.
53. Saadati F, Moritz J, Berner J, Freund E, Miebach L, Helfrich I, et al. Patient-derived human basal and cutaneous squamous cell carcinoma tissues display apoptosis and immunomodulation following gas plasma exposure with a certified argon jet. Int J Mol Sci 2021; 22:11446.
54. Exposito F, Redrado M, Houry M, Hastings K, Molero-Abraham M, Lozano T, et al. PTEN loss confers resistance to anti–PD-1 therapy in non–small cell lung cancer by increasing tumor infiltration of regulatory T cells. Cancer Res 2023; 83:2513-2526.
55. Toyozawa S, Kaminaka C, Furukawa F, Nakamura Y, Matsunaka H, Yamamoto Y. Chemokine receptor CXCR4 is a novel marker for the progression of cutaneous malignant melanomas. Acta Histochem Cytochem 2012; 45:293-299.
56. Mitchell B, Leone D, Feller JK, Bondzie P, Yang S, Park H-Y, et al. Correlation of chemokine receptor CXCR4 mRNA in primary cutaneous melanoma with established histopathologic prognosticators and the BRAF status. Melanoma Res 2014; 24:621-625.
57. Longo‐Imedio MI, Longo N, Treviño I, Lázaro P, Sánchez‐Mateos P. Clinical significance of CXCR3 and CXCR4 expression in primary melanoma. Int J Cancer 2005; 117:861-865.
58. Scala S, Ottaiano A, Ascierto PA, Cavalli M, Simeone E, Giuliano P, et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res 2005; 11:1835-1841.
59. Duda DG, Kozin SV, Kirkpatrick ND, Xu L, Fukumura D, Jain RK. CXCL12 (SDF1α)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin Cancer Res 2011; 17:2074-2080.
60. André ND, Silva VAO, Watanabe MAE, De Lucca FL. Knockdown of chemokine receptor CXCR4 gene by RNA interference: effects on the B16-F10 melanoma growth. Oncol Rep 2016; 35:2419-2424.
61. D’Alterio C, Buoncervello M, Ieranò C, Napolitano M, Portella L, Rea G, et al. Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1. J Exp Clin Cancer Res 2019; 38:1-13.
62. Katayama A, Ogino T, Bandoh N, Nonaka S, Harabuchi Y. Expression of CXCR4 and its down-regulation by IFN-γ in head and neck squamous cell carcinoma. Clin Cancer Res 2005; 11:2937-2946.
63. Semmler ML, Bekeschus S, Schäfer M, Bernhardt T, Fischer T, Witzke K, et al. Molecular mechanisms of the efficacy of cold atmospheric pressure plasma (CAP) in cancer treatment. Cancers 2020; 12:269.
Iranian Journal of Basic Medical Sciences

Articles in Press, Accepted Manuscript
Available Online from 01 June 2026

Files

Share

How to cite

Statistics